Nutriband Inc. (NTRB) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended July 31, 2026. Nutriband Inc. is a Nevada corporation focused on developing transdermal pharmaceutical products, primarily utilizing its proprietary AVERSA abuse-deterrent technology. The company operates through two main segments: Pocono Pharmaceuticals (contract manufacturing and sales of goods) and 4P Therapeutics (research and development of pharmaceutical products). The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Three Months Ended July 31, 2026 | Six Months Ended July 31, 2026 |
|---|---|---|
| Revenue | $437,514 | $870,913 |
| Gross Profit | $182,874 | $378,675 |
| Gross Margin | 41.8% | 43.5% |
| Net Loss | $(880,561) | $(2,122,517) |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.17) |
| Cash and Cash Equivalents | $3,421,615 (as of July 31, 2026) | |
| Working Capital | $2,912,335 (as of July 31, 2026) | |
| Total Debt (Current + Long-Term) | $153,541 | |
| Operating Cash Flow (6 Months) | $(1,148,103) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 29.7% year-over-year for the three months ended July 31, 2026 ($437,514 vs. $622,452) and 32.5% for the six-month period ($870,913 vs. $1,289,884). Management attributes this to a principal customer moving operations to Asia and the wind-down of the main contract in the 4P Therapeutics segment.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses dropped significantly, from $1,597,540 to $750,317 for the three-month period, primarily due to reduced compensation-based expenses. R&D expenses also decreased from $562,554 to $322,194 due to reduced labor costs.
- Improved Net Loss: While the company remains unprofitable, the net loss for the three months ended July 31, 2026, was $(880,561), a significant improvement compared to the prior year period which included a non-cash preferred stock dividend of $21.8 million, resulting in a reported loss available to common shareholders of $(23.8 million).
- Cash Position: Cash and cash equivalents decreased by approximately $1.15 million during the six-month period, driven by operating cash outflows of $1.15 million.
Guidance, Outlook, and Risks
- Going Concern: Management believes substantial doubt about the company's ability to continue as a going concern is alleviated based on current cash reserves ($3.4M) and a $5M credit line facility with a related party. However, the company continues to rely on equity financing and debt to fund operations.
- Product Development: The primary focus remains on the development of AVERSA Fentanyl. The company has incurred $5.2 million in expenses under its agreement with Kindeva Drug Delivery and expects to incur approximately $3.2 million more to complete development through NDA submission. A milestone payment of $3.0 million is due to Kindeva upon FDA approval.
- Legal Proceedings: The company is a defendant in a lawsuit initiated by Joseph Gunnar, LLC, and Lucosky Brookman LLP, alleging breach of contract and fraudulent activities. Plaintiffs seek over $500,000 in damages plus punitive damages. The company has filed counterclaims seeking $2 million in total damages. The case is currently in the discovery stage.
- Internal Controls: Management disclosed material weaknesses in internal controls over financial reporting due to a lack of segregation of duties and reliance on third-party consultants, though they have recently added qualified accounting personnel.
- Market Risks: Risks include the outcome of geopolitical conflicts (specifically mentioning a war with Iran), FDA approval uncertainties, and the volatility of the stock market.
Key Facts for Investor Verification
- Revenue Concentration: Verify the impact of the principal customer moving operations to Asia on future revenue streams from the Pocono Pharmaceuticals segment.
- Capital Sufficiency: Confirm the status of the $5,000,000 related-party credit line and the company's ability to raise additional capital to fund the remaining $3.2 million required for AVERSA Fentanyl development.
- Legal Exposure: Monitor the status of the Gunnar/LB lawsuit and the potential financial impact of the $500,000+ claim and counterclaims.
- Preferred Stock Dividend: Note the issuance of 3,008,643 shares of Series A Convertible Preferred Stock in July 2025 as a dividend, which may impact future capital structure and dilution upon conversion.
- Internal Control Remediation: Assess the effectiveness of the new internal controls implemented to address the previously disclosed material weaknesses.